Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407181 | 0.89 | MAPT (0.40) | MAPTMAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL25407187 | 0.89 | MAPT (0.40) | MAPTMAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL30528203 | 0.87 | USP30 (0.41) | USP30BRD4MAPTMAPK1ALDH1A1 | |
| SCHEMBL26584992 | 0.87 | USP30 (0.43) | USP30BRD4MAPTMAPK1ALDH1A1 | |
| SCHEMBL30461711 | 0.81 | USP30 (0.46) | USP30MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL25268000 | 0.81 | USP30 (0.46) | USP30MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL29467204 | 0.81 | MAPT (0.49) | USP30MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL28694487 | 0.81 | MAPT (0.49) | USP30MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL29467203 | 0.81 | MAPT (0.49) | USP30MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL28694485 | 0.81 | MAPT (0.49) | USP30MAPTMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | USP30 809/4885BRD4 1321/4885MAPT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.